|Year : 2020 | Volume
| Issue : 5 | Page : 347-355
Novel therapeutic approaches toward Hantaan virus and its clinical features’ similarity with COVID-19
Harvinder Singh, Harpinder Kaur, Bikash Medhi
Department of Pharmacology, PGIMER, Chandigarh, India
|Date of Submission||15-Oct-2020|
|Date of Decision||19-Oct-2020|
|Date of Acceptance||09-Nov-2020|
|Date of Web Publication||5-Dec-2020|
Dr. Bikash Medhi
Department of Pharmacology, PGIMER, Chandigarh
Source of Support: None, Conflict of Interest: None
Zoonotic virus spill over in human community has been an intensive area of viral pathogenesis and the outbreak of Hantaan virus and severe acute respiratory syndrome coronavirus 2 (SARS CoV2) after late December 2019 caused a global threat. Hantaan virus is second to the COVID-19 outbreak in China with seven cases positive and one death. Both RNA viruses have opposite sense as in (−) for Hantaan virus and (+) for SARS CoV2 but have similarity in the pathogenesis and relevant clinical features including dry cough, high fever, shortness of breath, and SARS associated with pneumonia and certain reported cases with multiple organ failure. Although COVID-19 has global impact with high death toll, Hantaan virus has varyingly high mortality rate between 1% and 40%. Hence, there is a need to explore novel therapeutic targets in Hantaan virus due to its rapid evolution rate in its genetic makeup which governs virulence and target host cells. This review emphasizes the importance of structural and nonstructural proteins of Hantaan virus with relevant insight from SARS CoV2. The envelope glycoproteins such as Gn, Gc, and nucleocapsid protein (N) direct the viral assembly and replication in host cells. Therapeutic treatment has similarity in using ribavirin and extracorporeal membrane oxygenation but lack of efficacious treatment in both cases of SARAS CoV2 and Hantaan virus. Therefore, potential features regarding therapeutic targets for drug discovery for Hantaan viruses are discussed herewith. The conclusive description highlights that N protein is substantially involved in evoking immune response and induces symptoms and could be precursive target for drug discovery studies.
Keywords: COVID-19 pathogenesis, diagnostics, Hantaan virus life cycle, therapeutic targets, treatments
|How to cite this article:|
Singh H, Kaur H, Medhi B. Novel therapeutic approaches toward Hantaan virus and its clinical features’ similarity with COVID-19. Indian J Pharmacol 2020;52:347-55
|How to cite this URL:|
Singh H, Kaur H, Medhi B. Novel therapeutic approaches toward Hantaan virus and its clinical features’ similarity with COVID-19. Indian J Pharmacol [serial online] 2020 [cited 2021 Jan 25];52:347-55. Available from: https://www.ijp-online.com/text.asp?2020/52/5/347/302495
| » Introduction|| |
There are two outbreaks of Hantaan virus in the past century, there is recent outbreak in China. In China, Hantaan virus outbreak reported by one death and seven cases found positive is another concern for researcher and health-care community after COVID-19. Hantaan virus was firstly reported in 1950 in South Korea characterized as a causative agent of hemorrhagic fever with renal syndrome (HFRS). The virus evolved along the time and second outbreak happened in the US in the 1990s decade with alternate symptoms or target system was known as Hantaan virus pulmonary syndrome (HPS). Hantaan viruses are directly transmitted through rodents; the mode of transmission is airborne (contact with infected aerosols of rodent excreta: urine, feces, and saliva). Human-to-human transmission is mediated via aerosols as COVID-19 known as communicable disease. This was more associated with cardiopulmonary dysfunction than HFRS. The mortality rate is also high (1%–40%) due to vital systems which are major targets such as the kidney, lungs, and cardiac systems. According to the International Committee on Taxonomy of Viruses (ICTV) classification, it belongs to a large family which comprises more than 300 viruses known as Bunyaviridae. Hantaan virus classified under the genus Hantaan virus has a negative sense single-stranded RNA segmented into three segments named large (L), small (S), and medium (M), it makes up total genome 11–19 kb enveloped with lipid membrane embedded of spike proteins. The different genuses of rodents have been reported for their ability to reserve the infectious agents without symptoms like HPS or HFRS. The reason behind no symptoms in rodents is uncertain; some studies suggest that rodents have efficient immunoregulatory cells to suppress the immune response against virus and prevent tachycardia and pulmonary edema. The reported genus of rodents as a reservoir includes Myodes, Apodemus, and Rattus. This diversity makes it a more sporadic nature of spread throughout the wide geographic locations. The actual prevalence is hard to know due to lack of testing tools in tropical countries like India and South Africa. Even there can be more than one million cases per year globally and bigger part belongs to China only. There is no specific treatment against HFRS and HPS, only symptomatic treatment like intensive care during severe respiratory distress by providing ventilation with oxygen therapy. In contrast of clinical course of Hantaan virus, we are reviewing the literature to find out the future prospective in therapeutic development. Identification of therapeutic targets might be essential for therapeutic development against the Hantaan virus.
| » Life Cycle|| |
Both COVID-19 and Hantaan viruses are a member of zoonotic viruses which is emerged from animals like bat and rodents, respectively, but belongs to the family of positive RNA stranded known as Coronaviridae and Bunyaviridae, respectively, Hantaan virus infects first lining cells of the lungs (endothelial cell and epithelial cells) and first-line immunogens such as macrophages, dendritic cells, and lymphocytes. Since these cells have surface expression of special receptor which is receptive for viral envelope surface glycoproteins named Gn and Gc encoded by medium segment of the single-stranded RNA genome. This specific cell surface receptors are integrins (beta-3) commonly involved in the attachment to host cell whether SARAS CoV-2 binds to the target cell via surface spike protein (15–20 nm) to angiotensin convertase enzyme-2 receptor. After the attachment, the virus enters the cell via clathrin-coated pits with the envelope (intact), but in the case of SARAS CoV2, the envelope remains outside only RNA and RNA proteins are released into the cytoplasm. In case of Hantaan virus, it has an additional step, is endo-lysosome formation which lyse the envelope and releases negative sense single stranded RNA and viral ribonucleic proteins into the cytoplasm. Now, the negative-sense RNA is available for early transcription which is required for the replication of viral RNA. Viral RNPs bind on a specific sequence known as a promoter region and initiates the early transcription to make three segments of the genome, namely small, large, and medium. These segments encode for specific proteins like nucleoprotein known as nucleocapsid (N) protein, viral RNA proteins, and envelope proteins encoded by respective segments. It also contains a nonstructural protein-encoding open reading frame (ORF) similar to Orthobunyaviridae family. Positive-sense ssRNA genome of SARAS CoV2 has capped at 5’end, multiple ORFs total composed of 26–32 kb genome is organized in the sequential manner of 5’ UTR replicase SMN UTR 3’ end. S encodes for spike, M for membrane, and N for nucleocapsid protein. It has RNA-dependent RNA polymerase (RdRp) found in the Hantaan virus for the replication and assembly of virus takes place near the smooth endoplasmic reticulum (ER) and early Golgi transition. These ORFs are responsible for stimulating the interferon response, they express during immune response phase of pathogenesis., Several studies suggested that it also plays an important role in the modulation of immune response in the infection. M transcript encodes for envelope protein precursor, which proteolytically modified into Gn and Gc proteins in the ER. This modification occurs co-translationally and then glycosylated along cleavage. After the glycosylation, it is transported to the Golgi complex. Protein processing in the case of SARAS CoV2 happens in the SER which involves various proteases (totally 16, but four is essential) known as a nonstructural protein. The next step in the life cycle is the switching of RNA transcriptase to RNA polymerase to replicate the viral genomes. Multiple copies of viral native RNA are ready to encapsidated. N protein plays a key role in trafficking the assembly material like surface proteins and viral RNA. This step is done with the help of microtubule dynein protein-mediated near the membrane of ER-Golgi intermediate complex (ERGIC). The bud is released outside of the infected cell by secretory vesicle (ICTV).
| » Pathogenesis|| |
HPS has very complex pathogenesis. It activates intense immune response which leads to vascular permeability increase. Due to vascular permeability increase, patients lead to pulmonary edema and a massive reduction in respiration efficiency which results in respiratory system failure and cardiogenic arrest. Processed antigen of viral N or spike protein is presented to the CD8+ T cell., Macrophages also present the same antigen to the cytotoxic T–cells, while presenting antigen, it secretes the pro-inflammatory cytokines like interleukin (IL) 6 and 1 and tumor necrosis factor alpha; a reason behind cardiogenic shock is due to suppressive effect on myocardial function and leads to the hypotensive condition.[18-20] The increased level of pro-inflammatory cytokines calls the specific T-cells by increasing the vascular permeability. Vascular permeability in the endothelial cells of the lung represents a critical condition in the disease development. Hantaan virus-infected cells evoke immune response but do not commit to programmed cell death by upregulation of survival factor BCL-2. Specific T-cells differentiate into the T helper (Th) cells named Th1 and Th2. Inducible regulatory T-cell secretes IL-10 and transforming growth factor (TNF) beta, these are the only two regulatory cytokines that suppress the immune response to get hyperactive and sustain the pathogenesis from worsening.,
COVID-19-infected patients show high blood plasma level of pro-inflammatory cytokines as Hantaan virus. Temperature of the body has risen up to 39°C and leukopenia by increasing number of neutrophils in circulation count with 70% of TLC 2.91 × 109 cells/L. High erythrocyte sedimentation rate and C‐reactive protein level increased by 1.5 fold to the normal range. IL-2, IL-7, IL-10, granulocyte colony-stimulating factor, IP10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1a, and TNF-a increase the level of severity in condition. Conclusively, the surge of pro-inflammatory cytokines such as IL-6, IL-12, IL-5, IL-2, TNF-alpha, TNF beta, and IFN-gamma and deficient in TGF beta and IL-10 play a key role in pathogenesis.
| » Clinical Features of Hantaan Viral Disease|| |
The new world Hantaan virus causes HPS which is associated with severe acute respiratory syndrome (SARS) and respiratory distress. The mortality rate depends on the strain which is infecting. First respiratory symptoms occur after 1–5 weeks. Actually, symptoms start with mild fever, myalgia, and weakness. HPS is represented to clinical as a distress in respiration followed by 2–3 days, it produces leakage in pulmonary capillaries, called by the leaking syndrome. Leaking syndrome leads to cardiogenic shock characterized by hypotensive in nature. Some patients report nausea, gastrointestinal symptoms, vomiting, and diarrhea. Prodrome symptoms are no longer than 4–5 days. It is followed by cough, dyspnea, tachycardia, and low atrial blood pressure. Respiratory failure is indicated by the cyanosis. It can lead to the hypotension and shock. Failure of renal function is due to the raised level of creatinine. Intestinal bleeding also is observed in some cases. Aspartate aminotransferase and alanine aminotransferase levels also raised in blood. Vascular permeability also increased which leads to the alveolar edema.,
In case of COVID-19, symptoms precipitate after 5–6th day after exposure. After the onset of symptoms, deaths happen in the range between 6 and 41 days having a median of 14th day. Symptoms are high temperature, cough, myalgia, headache, hemolysis, dyspnea, lymphopenia, and diarrhea.,, Acute respiratory distress syndrome, cardiogenic injury, grand-glass like opacities lead to death., It shows uniqueness in symptoms like sneezing, cough and sore throat by infecting both of lower and upper respiratory tract.,, Pulmonary edema takes place after immune response due to vascular permeability and causes hypoxemia.
| » Diagnostic Features|| |
HPS commonly diagnosed by the serological methods by the detection of antibodies against viral N protein; immunoglobulin G (IgG) and IgM in the circulation. Another diagnostic method is conventional molecular technique like reverse transcription–polymerase chain reaction (RT-PCR), it is a useful technique, which can reveal the viral genome at the 1st day of symptoms from infected tissue, blood, and serum.
For the COVID-19 diagnosis, RT-quantitative PCR (qPCR) is performed, which provides confirmatory and standardized results for coronavirus infection by amplifying the ORFs using specific primers for replicase and N protein. Its efficiency and sensitivity rate is also quite high as 91% from saliva samples collected from patients. Another method such as computed tomography scan and serological-based diagnostics such as IgG/M enzyme-linked immunosorbent assay kits are developed showing higher sensitivity than RT-qPCR, but further studies are needed for accuracy and efficiency.,
| » Treatment|| |
Till date, no antiviral or vaccine is approved by the Food and Drug Administration for Hantaan virus infection whether chloroquine, remdesivir, and ivermectin are approved for compassionate use in COVID-19 patients. Extracorporeal membrane oxygenation (ECMO) is initiated in patients who progress to advanced Hantaan virus cardiopulmonary syndrome (HCPS) and SARAS CoV2 severe cases, it needs to be started immediately on development of advanced shock or respiratory failure. Mertz et al. have shown a good survival rate with ECMO in HCPS patients. Among antivirals, ribavirin is the only one that has been evaluated in clinical trials. Ribavirin (intravenous, loading dose of 33 mg/kg, 16 mg/kg every 6 h for 4 days, and 8 mg/kg every 8 h for 3 days) decreased the severity of HFRS, however, it did not show any benefit in a controlled clinical trial for HCPS treatment in Canada and the US. Further, due to the fact that cardiopulmonary phase is mediated by immune system, methylprednisolone was evaluated for HCPS in a controlled clinical trial in Chile. Lactoferrin, 1-beta-d-ribofuranosyl-3-ethynyl- [1, 2, 4] triazole ETAR, favipiravir, and vandetanib have been evaluated in in vitro and in vivo studies for treatment of hantavirus infection. Human neutralizing antibodies administered at the time of acute phase of HCPS may have efficacy in treatment/prophylaxis of infection. Protection by neutralizing monoclonal antibodies (mAbs) and polyclonal sera has been reported by studies carried out in animal models. Further, Xiao et al. reported that decreased viremia levels at the time of admission to the hospital were related to less severe HCPS. A nonrandomized clinical trial in Chile for treating HCPS caused by Andes virus by human immune plasma reported its borderline statistically significant benefit.,
Killed-virus vaccine is associated with concern such as dangers related to mass production of virus and doubts regarding effectiveness. However, inactivated vaccines developed in cell culture for Hantaan virus (HTNV) and Seoul virus (SEOV) are in use in China and a formalin-inactivated vaccine (Hantavax®) made by growing HTNV in suckling mouse brain is in use in Korea. Approaches for vaccine development involve M segment products, recombinant N protein, SNV S gene-based and Puumala-truncated S gene-based DNA vaccine, etc.[Table 1].,
Preclinical data on the Hantaan virus are shown in a study by Sanna et al., several 2-phenyl-benzotriazoles resulted in fairly potent inhibitors of the Hantaan virus in a chemiluminescence focus reduction assay showing an EC50 = 4–5 mM, tenfold more active than ribavirin. Antiviral activities and cytotoxicity profiles suggest that 5,6-dichloro-1(2)-phenyl-1(2)H-benzo[d] [1, 2, 3] triazoles could be promising candidates for further investigation as a potential treatment of Hantaan viral diseases.
COVID-19 declared pandemic by the World Health Organization and treatment options are still remained bottleneck. Some of the important treatment options that are being evaluated for COVID-19 include hydroxychloroquine, ivermectin, antivirals, corticosteroids, mAbs, convalescent plasma therapy, mesenchymal stem cells, Traditional Chinese Medicine, and Traditional Indian Medicine [Table 2]. Hydroxychloroquine is also used for prophylaxis of COVID-19 infection. Ivermectin has potential for use in COVID-19 and is safe at higher doses and frequent regimens. Its efficacy in COVID-19 has been reported by in vitro as well as clinical studies. Various antivirals that have shown potential for use in COVID-19 such as remdesivir, ribavirin, favipiravir, lopinavir, etc., target RdRp, papain-like proteinase, 3-chymotrypsin-like proteinase, S protein, or TMPRSS2. Corticosteroids including dexamethasone, methylprednisolone, and prednisone are being used in COVID-19 treatment. Further, immunotherapy is considered an effective method for treatment of infectious diseases and mAbs such as canakinumab are being evaluated for use in COVID-19. Maximum benefit of plasma therapy is seen when it is given as prophylactic or early after the appearance of symptoms. Convalescent plasma therapy has shown beneficial effects during previous outbreaks and is now being evaluated for COVID-19. There are still needs to develop efficacious treatment to sustain the pandemic. More reliable therapeutic approaches like establishing new therapeutic targets, drug repurposing, and network-based analysis for available clinical data are required.
|Table 2: Some important treatment options that are being evaluated for use in coronavirus Disease-19|
Click here to view
| » Prospective Therapeutic Targets|| |
As we know, the advancement in the drug discovery by the in silico or computational methods can help to develop new small molecules if there are suitable or appropriate therapeutic targets that have been defined. On the basis of available literature about pathogenesis, we are suggesting the following appropriate therapeutic targets.
| » Viral Spike Proteins|| |
Envelope surface proteins such as Gc and Gn appear like spikes or needle projections known as spike protein. These proteins are embedded in the lipid layer of the virus envelope. Spike protein is encoded by M segment of the viral RNA. Each spike protein is a hetero dimer of Gn and Gc which have a large globular domain, a transmembrane domain, and a cytoplasmic short tail. Virus has no matrix proteins so it was suggested that N protein directly interacts with the cytoplasmic tail of spike protein., Cytoplasmic tail domain has a highly conserved zinc finger motif which plays a key role in assembly and trafficking of the viral genome and proteins. Gn and Gc are processed in the Golgi complex by adding N terminal glycosylation. Somewhere, there is a transition phase of ER and Golgi body known as ERGIC ER Golgi complex where the assemble of the virion particles happens. The spike protein is very specific to the beta-3 integrin receptor present on the host endothelial, epithelial, macrophages, and dendritic cells which permits entry of the virion. Hence, conclusively, spike protein assembly and modification can be a good therapeutic target. This spike protein is lysed by the late endosome and processed for antigen presentation which is a key feature in virulence and activation of innate immune response takes place. Degraded Gn protein’s cytoplasmic tail interacts with the transcription factor of IFN beta (TRAF3) and starts replication within the host cell by inhibiting the viral elimination pathway of innate immune system [PDB ID in [Table 3]].
|Table 3: Structures of potential prospective therapeutic targets with their properties and source [reference]|
Click here to view
| » Nucleocapsid Protein|| |
N protein is a major constituent of the viral RNA protein which found the bound with viral RNA. It consists of 433 amino acid residues approximated size of 50 kDa. It has a specific conserved sequence decides which segment is to be translated first. In the early infection stage, N protein expressed in the cytoplasm and innate immune system evoked against N protein. N protein plays a pivotal role in encapsidation and protection of viral RNA from degradation by the host endonucleases. Viral RNA has 23 ribonucleotide sequences at 5’ terminal which is complementary to self-terminal and has high affinity to the N protein. This conserved sequence is the binding site for RdRp which synthesizes the complementary or positive-sense RNA and works as mRNA to synthesize the proteins.
N protein also binds with IRF3 (transcription) which is found in the cytoplasm and regulates the expression of MxA protein. IRF3 works as a transcription factor and translocates in the nucleus in the response of viral infection. MxA protein is the component of IFN which helps in antiviral activity of host cell. N protein efficiently binds with IRF3 and inhibits the translocation to nucleus of IRF3. Hence, viral infection is negatively correlated to the expression of MxA protein. As mentioned above, the N protein in the pathogenesis represents as a bottleneck to control the replication of virus and further development of the critical condition [PDB ID in Table 3].
| » RNA Dependent RNA Polymerase|| |
RdRp is an enzyme which works as transcriptase and replicase using viral RNA as a template. The presence of RdRp is essential for the viral replication and transcription. If RdRp inhibition is performed, the early expression of the N protein can be prevented. It also can work as an initial bottleneck for replication prevention [PDB ID in Table 3].
| » Virus L-protein|| |
Hantaan virus has an adaptation tool known as an L-protein. It acts as a 5’ cap snatching endonuclease means it is responsible for degradation of host cytoplasmic mRNA at the 5’ end and releases the 5’ ended cap (methylation). This cap has to be transferred to the viral mRNA (used as a primer for RNA synthesis) and it protects from the attack of host cell endonuclease digestion [PDB ID in Table 3].
| » Discussion|| |
The emerging of Hantaan virus cases is the next issue after the COVID-19, both are deadly viruses with comorbid conditions. Hantaan virus has epidemic nature in outbreak along seasonal variation regarding rural areas where raw material is most probably used manifested with a natural reservoir of Hantaan virus (rodents). It has a high mortality rate, so here we illustrated the pathogenesis and clinical features of the Hantaan virus along with potential therapeutic targets. These targets can be critical to control the pathogenesis, designing potential inhibitor or inducer small molecules. There are less clinical trial data which are available regards Asian countries except China and Korea. Further studies required to design the small molecules against potential therapeutic targets. However, there are many hurdles in the small molecule testing like unavailability of suitable animal models.There is no potential molecule is reported till date which cleared all the stages of drug development pipeline i.e. preclinical and clinical platforms. Only one ribavirin is reported which works efficiently in the in vitro and hamster model of Hantaan virus and SNV virus infection but lacks the efficacy in the patients presenting with Hantaan viral infection. Another treatment option is vaccination Green Cross Corporation (GCC) developed by ROK (HantavaxTM) Company • CEO • Specialty • Location • Homepage Green Cross Corp.Il-Sup, Huh Plasma derivatives, Recombinant Proteins, Vaccines, ETC & OTC products 107, Ihyeon-ro, 30 beon-gil, Giheung-gu, Yongin, Korea, also lacks the efficacy to immune for the long time. Booster dose is to be required and dosing schedule has to be standardized. Major drawback of available treatment option is the adverse event and suitability is also a concern in the respect of vaccination.
On the basis of available literature, we are suggesting potential therapeutic targets which might play a vital role in sustain the pathogenesis. Several analytical tools are available to prove the potentiality of the targets that are required, for example, network-based studies, Network-based analysis, human viral interactome analysis, etc., genome-wide association studies and network-based analysis might give a mechanistic insight into the pathogenesis and treatment options. Computational biology also can be an efficient tool to repurposing the drugs with known efficacy and target hit scores. There are many gray areas in pathogenesis which have to be clarified by further clinical research based.
This study has limitations regarding availability of less clinical research studies’ data. In vitro and animal studies are available, but their results cannot be extrapolated to clinical setup.
| » Conclusion|| |
After reviewing the available literature, we suggest that therapeutic targets like N protein interaction with the innate immune system and unbalancing between regulations of immune response lead to pathogenesis. Other targets might be spike proteins, cap snatching L protein, and RdRp, these targets are essential for viral replication and in pathogenesis. Another symptomatic therapeutic target can be immune suppression like an antagonist of cytokine surges and booster of regulatory immunogens.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| » Web References|| |
Virus Taxonomy: 2009 Release ICTV 9th Report, EC41: Leiden, June 2009; Email ratification 2009 (MSL #25) Bunyaviridae: 5 genera, 95 species. Available from: https://talk.ictvonline.org/ictv-reports/ictv_9th_report/negative-sense-rna-viruses2011/w/negrna_viruses/205/bunyaviridae.
| » References|| |
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020;10:102-8.
Jonsson CB, Figueiredo LT, Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev 2010;23:412-41.
Iannetta M, Di Caro A, Nicastri E, Vairo F, Masanja H, Kobinger G, et al
. Viral hemorrhagic fevers other than Ebola and Lassa. Infect Dis Clin North Am 2019;33:977-1002.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433.
Elliott RM. Molecular biology of the Bunyaviridae. J Gen Virol 1990;71(Pt 3):501-22.
Schountz T, Prescott J, Cogswell AC, Oko L, Mirowsky-Garcia K, Galvez AP, et al
. Regulatory T cell-like responses in deer mice persistently infected with Sin Nombre virus. Proc Natl Acad Sci U S A 2007;104:15496-501.
Lee HW, Lee PW, Johnson KM. Isolation of the etiologic agent of Korean Hemorrhagic fever. J Infect Dis 1978;137:298-308.
Lee HW. Epidemiology and pathogenesis of hemorrhagic fever with renal syndrome. In: Elliott RM, editor. The Bunyaviridae. Boston, MA: Springer US; 1996. p. 253-67. Available from: http://link.springer.com/10.1007/978-1-4899-1364-7_10
. [Last accessed on 2020 Apr 05].
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. J Med Virol 2020;92:441-7.
Yamauchi Y, Helenius A. Virus entry at a glance. J Cell Sci 2013;126:1289-95.
Schmaljohn CS, Jennings GB, Hay J, Dalrymple JM. Coding strategy of the S genome segment of Hantaan virus. Virology 1986;155:633-43.
Mir MA, Duran WA, Hjelle BL, Ye C, Panganiban AT. Storage of cellular 5’ mRNA caps in P
bodies for viral cap-snatching. Proc Natl Acad Sci U S A 2008;105:19294-9.
Enria DA, Briggiler AM, Pini N, Levis S. Clinical manifestations of new world hantaviruses. In: Schmaljohn CS, Nichol ST, editors. Hantaviruses. Berlin, Heidelberg: Springer Berlin Heidelberg; 2001. p. 117-34. Compans RW, Cooper M, Ito Y, Koprowski H, Melchers F, Oldstone M, et al
., editors. Current Topics in Microbiology and Immunology. Vol. 256. Berlin, Heidelberg, Springer Berlin Heidelberg and publishing year 2001. Available from: http://link.springer.com/10.1007/978-3-642-56753-7_7
.[Last accessed on 2020 Apr 06].
Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. Beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S A 1998;95:7074-9.
Ennis FA, Cruz J, Spiropoulou CF, Waite D, Peters CJ, Nichol ST, et al
. Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology 1997;238:380-90.
Kilpatrick ED, Terajima M, Koster FT, Catalina MD, Cruz J, Ennis FA. Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. J Immunol 2004;172:3297-304.
Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
Janssen SP, Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken E, et al
. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005;111:996-1005.
Guidotti LG, Chisari FV. Noncytolytic Control of Viral Infections by the Innate and Adaptive ImmuneResponse. Annu Rev Immunol 2001;19:65-91.
Solà-Riera C, García M, Ljunggren HG, Klingström J. Hantavirus inhibits apoptosis by preventing mitochondrial membrane potential loss through up-regulation of the pro-survival factor BCL-2. PLoS Pathog 2020;16:e1008297.
Borges AA, Campos GM, Moreli ML, Souza RLM, Aquino VH, Saggioro FP, et al
. Hantavirus cardiopulmonary syndrome: Immune response and pathogenesis. Microbes Infect 2006;8:2324-30.
Khaiboullina S, Morzunov S, St. Jeor S. Hantaviruses: Molecular biology, evolution and pathogenesis. Curr Mol Med 2005;5:773-90.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al
. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
Chen LB, Yang WS. Abnormalities of T cell immunoregulation in hemorrhagic fever with renal syndrome. J Infect Dis 1990;161:1016-9.
Vial PA, Valdivieso F, Mertz G, Castillo C, Belmar E, Delgado I, et al
. Incubation period of hantavirus cardiopulmonary syndrome. Emerg Infect Dis 2006;12:1271-3.
Campos GM, Borges AA, Badra SJ, Figueiredo GG, Souza RL, Moreli ML, et al
. Síndrome pulmonar e cardiovascular por hantavírus: Aspectos clínicos de uma doença emergente no sudeste brasileiro. Rev Soc Bras Med Trop 2009;42:282-9.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al
. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199-207.
Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al
. Identification of a novel coronavirus causing severe pneumonia in human: A descriptive study. Chin Med J (Engl) 2020;133:1015-24.
Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al
. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect Dis 2013;13:752-61.
Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al
. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-94.
Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al
. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med 2020;382:872-4.
Amada T, Yoshimatsu K, Yasuda SP, Shimizu K, Koma T, Hayashimoto N, et al
. Rapid, whole blood diagnostic test for detecting anti-hantavirus antibody in rats. J Virol Methods 2013;193:42-9.
Ferres M, Vial P, Marco C, Yanez L, Godoy P, Castillo C, et al
. Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis 2007;195:1563-71.
Woo PC, Lau SK, Wong BH, Tsoi HW, Fung AM, Kao RY, et al
. Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. J Clin Microbiol 2005;43:3054-8.
Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 2020;295:18.
Mertz GJ, Hjelle B, Crowley M, Iwamoto G, Tomicic V, Vial PA. Diagnosis and treatment of new world hantavirus infections. Curr Opin Infect Dis 2006;19:437-42.
Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res 2008;78:162-9.
Brocato RL, Hooper JW. Progress on the prevention and treatment of hantavirus disease. Viruses 2019;11:610.
Sanna G, Piras S, Madeddu S, Busonera B, Klempa B, Corona P, et al
. 5,6-Dichloro-2-phenyl-benzotriazoles: New potent inhibitors of orthohantavirus. Viruses 2020;12:122.
Hossen MdS, Barek MA, Jahan N, Safiqul Islam M. A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN Comprehensive Clinical Medicine. 2020 Oct 1;2(10):1777–89.
Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al
. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130:2757-65.
Plyusnin A, Cheng Y, Lehv ~ Slaiho H, Vaheri A. Unique and conserved features of tula hantavirus M gene encoding envelope glycoproteins G1 and G2. Virus Genes 1996;12:257-263. Available from: http://link.springer.com/10.1007/BF00284646
. [Last accessed on 2020 Apr 05].
Deyde VM, Rizvanov AA, Chase J, Otteson EW, St Jeor SC. Interactions and trafficking of Andes and sin Nombre hantavirus glycoproteins G1 and G2. Virology 2005;331:307-15.
Battisti AJ, Chu YK, Chipman PR, Kaufmann B, Jonsson CB, Rossmann MG. Structural studies of Hantaan virus. J Virol 2011;85:835-41.
Severson WE, Xu X, Jonsson CB. cis-Acting signals in encapsidation of Hantaan virus S-segment viral genomic RNA by its N protein. J Virol 2001;75:2646-52.
Kanerva M, Melén K, Vaheri A, Julkunen I. Inhibition of puumala and tula hantaviruses in Vero cells by MxA protein. Virology 1996;224:55-62.
Malinin OV, Platonov AE. Insufficient efficacy and safety of intravenous ribavirin in treatment of haemorrhagic fever with renal syndrome caused by Puumala virus. Infect Dis 2017;49:514-20.
Song JY, Woo HJ, Cheong HJ, Noh JY, Baek LJ, Kim WJ. Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavax™) in healthy adults. Vaccine 2016;34:1289-95.
Rissanen I, Stass R, Zeltina A, Li S, Hepojoki J, Harlos K, et al
. Structural transitions of the conserved and metastable hantaviral glycoprotein envelope. Sundquist WI, editor. J Virol 2017;91:e00378-17.
Guardado-Calvo P, Bignon EA, Stettner E, Jeffers SA, Pérez-Vargas J, Pehau-Arnaudet G, et al
. Mechanistic insight into bunyavirus-induced membrane fusion from structure-function analyses of the Hantavirus envelope glycoprotein Gc. Kuhn RJ, editor. PLOS Pathog 2016;12:e1005813.
Olal D, Daumke O. Structure of the Hantavirus nucleoprotein provides insights into the mechanism of RNA encapsidation. Cell Rep 2016;14:2092-9.
Reguera J, Gerlach P, Rosenthal M, Gaudon S, Coscia F, Günther S, et al
. Comparative structural and functional analysis of bunyavirus and arenavirus cap-snatching endonucleases. PLoS Pathog 2016;12:e1005636.
Gerlach P, Malet H, Cusack S, Reguera J. structural insights into bunyavirus replication and its regulation by the vRNA promoter. Cell 2015;161:1267-79.
[Table 1], [Table 2], [Table 3]